SAMUEL BRODER was named executive vice president of scientific and public affairs at the Intrexon Corporation. The former director of NCI was most recently chairman of Intrexon's health sector.
THE PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE appointed 10 members to a new Advisory Panel on Clinical Trials. The panel will convene for its first meeting May 1 in Washington, D.C.
Current Medicare policies do not adequately reimburse cancer care provided in the community setting, the Community Oncology Alliance and the U.S. Oncology Network said in a joint, open letter to members of Congress.
Cancer research remains underfunded, and the U.S. cancer care system as a whole may be unprepared to handle an aging population, according to two separate reports from the American Association for Cancer Research and the American Society of Clinical Oncology.
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH has named its 2014 class of elected fellows of the AACR Academy. The fellows will be inducted at the association's annual meeting in San Diego, April 5-9.
The chairs of the adult clinical trials groups that make up the NCI National Clinical Trials Network said in a letter that recent budget cuts have triggered a “crisis” in clinical research.
The European Commission approved a subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Terminal cancer patients who receive chemotherapy in the last months of their lives are less likely to die where they want and are more likely to undergo invasive medical procedures than those who do not receive chemotherapy, according to a study.
An observational study found that robotic-assisted surgery for prostate cancer has fewer positive surgical margins than open surgery, and patients who had robotic surgery needed fewer additional cancer treatments afterward.
